moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Unregistered Sales of Equity Securities

Item 3.02

As previously disclosed in its public filings, Moleculin Biotech,
Inc. (the Company) had on various dates from August 31, 2015
through January 19, 2016, issued 8% unsecured promissory notes to
certain accredited investors to an exemption from registration
under the Securities Act of 1933, as amended, in reliance on
Section 4(a)(2) thereof. Upon the completion of the Companys
initial public offering, these notes provided that they be
converted into shares of common stock at their applicable
conversion prices, to the extent and provided that no holder of
these notes was permitted to convert such notes to the extent
that the holder or any of its affiliates would beneficially own
in excess of 4.99% of the Companys common stock after such
conversion. Due to this 4.99% limitation, certain portions of the
issued notes remained outstanding subsequent to the Companys
initial public offering. As of March 31, 2017, the Company had
outstanding convertible notes in principal amount of
approximately $22,000, convertible at $0.20 per share, and
convertible notes in principal amount of approximately $86,000,
convertible at $0.1299 per share. On June 23, 2017, the foregoing
convertible notes of approximately $108,000 in principal amount,
plus accrued interest of approximately $4,000, was converted into
an aggregate of 804,037 shares of Company common stock. After the
completion of these conversion, the Company no longer has any
outstanding convertible notes.

On June 21, 2017, the Company issued a press release announcing
the discovery of a metabolic inhibitor with the potential to
treat pancreatic cancer. A copy of the press release is attached
to this report as Exhibit 99.1 and is incorporated by reference
herein.

On June 26, 2017, the Company issued a press release announcing
that it had entered into an agreement with a physician at the
Mayo Clinic to enable additional research on Moleculin’s WP1066
molecule for the possible treatment of a rare form of pediatric
brain tumor. A copy of the press release is attached to this
report as Exhibit 99.2 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.1, is being furnished and shall
not be deemed to be filed for the purpose of the Securities
Exchange Act of 1934, as amended (Exchange Act), nor shall it be
deemed incorporated by reference in any filing under the Exchange
Act or the Securities Act of 1933, as amended, unless
specifically identified therein as being incorporated by
reference.

(d)Exhibits.

Moleculin Biotech, Inc. Exhibit
EX-99.1 2 v469834_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines   HOUSTON – June 21,…
To view the full exhibit click here
About moleculin biotech, INC. (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.